

Application Report 298

Analysis of 3 Anti-inflammatory Therapeutics Using Ascentis™ C8

This application demonstrates the suitability of the Ascentis C8 for the analysis of anti-inflammatories. Structures along with the optimized chromatogram obtained on the Ascentis C8 are presented.


Key Words

etodolac, 41340-25-4, E0516, celecoxib, 169590-42-5, beclomethasone, 4419-39-0, B0385, Ascentis C8, 581424-U

Author: Hugh M. Cramer

Acquisition System: Hitachi Mt Fuji

Notebook Reference: 1558



G003155

Conditions


column: Ascentis C8, 15 cm x 4.6 mm I.D., 5 µm particles (581424-U)
mobile phase: 45:55, 10 mM ammonium formate (pH 3.0 with formic acid):acetonitrile
flow rate: 1.0 mL/min.
temp.: 35 °C
det.: UV at 254 nm
injection: 10 µL
sample: as indicated in mobile phase

Peak IDs


1. Beclomethasone (50 µg/mL)
2. Etodolac (50 µg/mL)
3. Celecoxib (50 µg/mL)

Structures


Beclomethasone - G003154



Etodolac - G003152



Celecoxib - G003153



Ascentis is a trademark of Sigma-Aldrich Co.